Pimozide was discovered in 1963 by Janssen Pharmaceutica and later underwent extensive research during the 1970s and early 1980s to evaluate its antipsychotic and anti-tic properties. Clinical studies began around 1977, which demonstrated its effectiveness in managing Tourette’s syndrome and other chronic tic disorders. Based on these findings, it was approved by the FDA in 1984 (with some sources citing 1985) as an orphan drug for the treatment of Tourette’s syndrome. Since then, pimozide has been recognized for its potent dopamine receptor-blocking activity, making it useful in specific psychiatric and neurological conditions.
BRAND NAMES
Orap
Orap Forte
Pimozide (various generic brands)
MECHANISM OF ACTION
Pimozide is a typical antipsychotic that acts mainly by blocking dopamine D2 receptors in the brain, especially in the mesolimbic pathway. This reduces excessive dopamine activity, helping to control psychotic symptoms such as hallucinations, delusions, and thought disturbances. It is also effective in reducing motor tics in Tourette’s syndrome by decreasing abnormal dopaminergic signaling in motor control pathways.
PHARMACOKINETICS
Absorption
Pimozide is well absorbed from the gastrointestinal tract after oral administration, but its bioavailability is variable due to significant first-pass metabolism in the liver. plasma Food may slightly increase absorption, but the clinical effect is generally not significantly altered.
Distribution
Pimozide is widely distributed throughout the body after absorption and is highly bound to plasma proteins, mainly albumin. It readily crosses the blood-brain barrier to reach the central nervous system, where it exerts its antipsychotic effects by acting on dopamine receptors. It also distributes into other tissues, contributing to its long duration of action.
Metabolism
Pimozide is extensively metabolized in the liver, mainly through CYP3A4 and CYP1A2 enzyme systems. It undergoes oxidative metabolism to form inactive metabolites. Because of its reliance on hepatic enzymes, its levels can be affected by drugs that inhibit or induce these cytochrome P450 pathways.
Elimination
Pimozide is eliminated slowly from the body, mainly through fecal excretion as metabolites via the biliary route, with a smaller portion excreted in urine. It has a long elimination half-life, which contributes to its prolonged duration of action and allows once-daily dosing in most cases.
PHARMACODYNAMICS
Pimozide exerts its pharmacological effects primarily by antagonizing dopamine D2 receptors in the central nervous system, especially in the mesolimbic pathway, which helps reduce positive symptoms of psychosis such as hallucinations and delusions. It also affects dopamine transmission in motor pathways, making it effective in reducing tics in Tourette’s syndrome.
ADMINISTRATION
Pimozide is administered orally, usually once daily due to its long half-life. The dose is started low and gradually increased based on patient response and tolerance. It can be taken with or without food, but consistent timing each day is recommended. Regular ECG monitoring is advised during therapy because of the risk of QT prolongation.
DOSAGE AND STRENGTH
Pimozide is typically initiated at a low dose of 1–2 mg once daily in adults and is gradually increased depending on clinical response and tolerance. The usual maintenance dose for schizophrenia and related psychotic disorders ranges from about 2–12 mg per day, while in Tourette’s syndrome lower doses such as 1–4 mg per day are generally effective. The dosage must be individualized carefully due to its potency and risk of cardiac adverse effects. Pimozide is available in tablet strengths of 1 mg and 2 mg, which allows precise dose titration.
DRUG INTERACTIONS
Pimozide has significant drug interactions, mainly due to its metabolism via CYP3A4 and CYP1A2 enzymes. Drugs that inhibit these enzymes (such as certain macrolide antibiotics, azole antifungals, and some antidepressants) can increase pimozide levels and raise the risk of QT prolongation and serious arrhythmias. It should not be used with other QT-prolonging drugs. Enzyme inducers (like carbamazepine or phenytoin) may reduce its effectiveness. Caution is also needed when combined with CNS depressants or other antipsychotics due to additive effects.
FOOD INTERACTIONS
Pimozide has minimal clinically significant food interactions. It can be taken with or without food, although taking it with food may slightly increase absorption in some patients. However, maintaining a consistent routine (same relation to meals each day) is recommended to avoid variability in drug levels and effect.
CONTRAINDICATIONS
Pimozide is contraindicated in patients with known hypersensitivity to the drug. It should not be used in individuals with congenital or acquired long QT syndrome, significant cardiac arrhythmias, or other conditions that predispose to QT prolongation due to the risk of life-threatening ventricular arrhythmias. It is also contraindicated in severe central nervous system depression, comatose states, and in combination with drugs that strongly inhibit CYP3A4 or markedly prolong the QT interval.
SIDE EFFECTS
Constipation
Weight gain
Hyperprolactinemia (galactorrhea, menstrual changes)
QT prolongation
Cardiac arrhythmias (rare but serious)
Blurred vision
Hypotension
Neuroleptic malignant syndrome (rare)
OVER DOSAGE
Pimozide overdose can cause severe extrapyramidal symptoms, sedation, hypotension, and significant cardiac effects such as QT prolongation and potentially life-threatening arrhythmias.
TOXICITY
Pimozide toxicity is mainly characterized by QT prolongation leading to dangerous arrhythmias, along with severe extrapyramidal symptoms, sedation, and hypotension. Treatment is supportive with ECG monitoring and correction of electrolyte imbalances.
